Aequus Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Rhea-AI Summary

Aequus Pharmaceuticals has received a new Medical Device License for its Evolve™ Intensive Gel aimed at treating Dry Eye Disease. This product is part of a preservative-free line developed in partnership with Medicom Healthcare. The gel contains a unique formulation designed to provide enhanced hydration for patients suffering from moderate to severe dry eye conditions. With this approval, Aequus anticipates that the Evolve line will become a significant revenue stream, as launch activities for the remaining products are currently underway.

Positive

• Approval of Evolve Intensive Gel expected to enhance revenue for Aequus.
• Evolve line addresses a significant market need, with 6.3 million Canadians affected by Dry Eye Disease.
• Partnership with Medicom Healthcare strengthens product credibility and market reach.

Negative

• None.

Aequus Announces Approval of Third Revenue Generating Product

VANCOUVER, British Columbia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today that together with its partner, Medicom Healthcare Ltd. (“Medicom”), has been issued a new Medical Device License for the first of three product submissions made for the Evolve^TM preservative free dry eye product line. The new Medical Device License has been issued for Evolve^TM Intensive Gel – a unique cross linked combination of Carbomer 980, Hyaluronate and glycerol – which act together to provide intensive, durable hydration for patients with moderate to severe forms of Dry Eye Disease. The formulation will be made available in an easy-squeeze eye drop bottle, containing 360 drops, and no preservatives, phosphates or buffers.

“Evolve Intensive Gel is a one-of-a-kind formulation in Canada, and is only the first of a full line of Eye Care Professional Exclusive products being launched by Aequus, that will not only improve treatment and compliance for better patient outcomes, but create an improved revenue stream for Eye Care professionals who spend additional time and resources treating dry eye patients in practice,” said Grant Larsen, Chief Commercial Officer at Aequus.

“We are delighted that our partner Aequus Pharmaceuticals has achieved approval of Evolve Intensive Gel by Health Canada. We know that long term use of preservatives will damage the cornea and the Evolve preservative free dry eye product line can help with the symptoms of dry eye whilst protecting the cornea from that damage,” said Simon Martin, founder and CEO of Medicom Healthcare. “Called Revive in other countries, this product is a revolutionary triple action matrix gel designed for lubrication, restoration & protection of the ocular surface, providing extended ocular residency time.”

“This approval marks an important step for Aequus,” said Aequus CEO Doug Janzen. “The Evolve line of products are going to be important revenue drivers for Aequus and we are pleased that Evolve Intensive Gel was the first approved. Launch activities for all three Evolve products are underway while the remaining two Evolve^TM products are currently under review for approval with Health Canada.”

ABOUT DRY EYE DISEASE

Dry eye disease (DED) is a common disorder of the tear film that leads to ocular surface damage over time. Previous research has shown DED reduces health and vision related quality of life and that it carries a considerable economic burden of disease. DED affects approximately 6.3 million Canadians, representing approximately 21% of the population.¹ Home confinement, e-learning and working from home due to the COVID-19 pandemic means spending more time looking at screens, which has a significant impact on eye health. A combination of reduced frequency and intensity of blinking during screen time increases the risk of inducing or exacerbating dry eye disease.²

1. B. Caffery, S. Srinivasan, C.J. Reaume, et al., Prevalence of dry eye disease in Ontario, Canada: A population-based survey, Ocul. Surf. 17 (2019) 526-531.
2. https://theophthalmologist.com/covid-19-and-dry-eye-disease; accessed October 15, 2020

ABOUT EVOLVE

Launched in 2015 in Europe, the Evolve^TM brand has grown to 5 products across 35 countries. With an array of products, the brand can address the various symptoms involved with dry eye disease and blepharitis including discomfort, stinging, burning, and dryness. Currently in Canada, the dry eye market is estimated at over $90M, which includes both prescription and over-the-counter products.

ABOUT AEQUUS PHARMACEUTICALS INC.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

FORWARD-LOOKING STATEMENT DISCLAIMER

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; revenue growth trends into the future; expected timing for product launch; the Company’s expected revenues; the regulatory approval of the Evolve line of products expected in 2020. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 28, 2020, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

CONTACT INFORMATION
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906

FAQ

What is Evolve Intensive Gel and its significance for Aequus Pharmaceuticals?

Evolve Intensive Gel is a new preservative-free eye drop product approved by Health Canada, expected to generate revenue and improve treatment for Dry Eye Disease.

How many Canadians suffer from Dry Eye Disease?

Approximately 6.3 million Canadians, or about 21% of the population, are affected by Dry Eye Disease.

What is the stock symbol for Aequus Pharmaceuticals?

The stock symbol for Aequus Pharmaceuticals is AQSZF, traded on OTCQB.

What are the future plans for Aequus Pharmaceuticals regarding Evolve products?

Aequus plans to launch additional products in the Evolve line, with two more currently under review for approval by Health Canada.